700 patients109,892 observations180 daysLIVE

Patient P-02299

Synthetic patientMETA-24 · Day 143 · 75+ · M · baseline S11Steering view · 3DOpen companion preview
Is the drug working?

Metabolic response 84 at the day-84 endpoint (observed).

Why responding?

Responding: response probability 92%, metabolic response 99 today; biology is not blocking the drug.

Is a side effect starting?

No side effect starting: nausea / gi symptoms 13, tolerability burden 9, no drift from the model.

Still taking it?

40 of 61 scheduled doses in the last 60 days are biologically confirmed (66%); 19 were logged but show no dose signature. Dose signature: resting HR +3 bpm, HRV −9 ms.

last 10 doses · green confirmed · amber logged only · red missed
Plan for this patient
stable, no actionrecommendowner · Companionreview day 150Human Model →
Next action
No action indicated; maintain.
Kept if

Trajectory is stable relative to similar patients; keep the current content.

Daily to-dos in the companion
  • 🍽Keep meals regular; three to four moderate portions spaced through the day
  • 🍽Include a cooked vegetable portion with each main meal
  • Log the daily check-in; one line is enough
  • Keep the current walking rhythm
  • 💊Take the dose at the same time relative to your evening meal
  • 💊No additional supplements this week
Adherence
88% worsening

Adherence is not the problem.

Changes the plan if

sleep quality falling under 35 while GI rises

LLIFE OS insight
grounded · add an LLM key for prose

P-02299 is on day 143 of META-24 (SR, baseline S11): response improving, tolerance favorable, GI improving. Over 14 days response moved +15 and GI -13; discontinuation risk is 9%. The state is between basins, heading towards restoration.

Butyrate capacity 53/100, diversity 4.6, normal metabolizer. Pushing it down: Escherichia coli 11.584% (LPS load) (-33.5), Tissue recycling 36/100 (-16.1), Antibiotic course (-4.7). Pulling it up: Protein (supports) (+26.2), Butyrate producers intact (+14.3). From the daily log: protein -6 GI next day.

No action has been tried yet.

No action is indicated now; the trajectory is stable relative to similar patients.

Therapy response
Improving
Tolerance
Favorable
GI state
Improving
Inflammatory state
Improving
Nutritional resilience
Improving
Discontinuation risk
9%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events
solid = observed · dashed = predicted · dose (daily oral dose, morning)
  1. Day 0 META-24 startedBaseline state S11

What changed?

Trajectory is tracking the baseline prediction.

Primary contributors, last 14 days
  • GI instability-13
  • Inflammatory activity-10
  • Nutritional resilience+6
  • Treatment adherence-5

What helped?

No interventions yet.

    LIFE OS recommendation
    No intervention is indicated right now. The trajectory is stable relative to similar patients. See what worked for similar patients.

    Daily trackers

    Asset settings

    The trackers this program marks as important, last 14 days vs the 14 before.

    Glucose, CGM daily mean
    CGM
    130 mg/dL
    stable · +2.9 vs previous 14 d
    Active minutes
    Wearable
    71 min
    stable · +1.2 vs previous 14 d
    Sleep duration
    Wearable
    7.7 h
    stable · +0.1 vs previous 14 d
    Energy level
    Daily log
    7.1/10
    stable · +0.0 vs previous 14 d
    Steps
    Wearable
    8,358
    stable · -153 vs previous 14 d
    GI burden
    Companion
    12.9/100
    worsening · +2.8 vs previous 14 d
    Adherence
    Companion
    88 %
    worsening · -6.3 vs previous 14 d
    This trajectory is doing well — what to keep, what to watch
    Steering view →

    Heading towards restoration · 105 from the failing basin, 22 from restoration.

    Good elements to keep
    • Protein (supports)
      perturbation · steering +26.2
    • Butyrate producers intact
      hidden · steering +14.3
    • Daily walks resumed
      perturbation · steering +3.3
    • Protein
      supporter · GI -6 next day
    Main detractors to watch
    • Escherichia coli 11.584% (LPS load)
      hidden · steering -33.5
    • Tissue recycling 36/100
      hidden · steering -16.1
    • Antibiotic course
      perturbation · steering -4.7
    • Low-HRV stretch
      perturbation · steering -2.7
    State influencers · digestive

    Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.

    • Protein
      -6supporter · 95%
    • Ultra-processed food
      +2.5no signal · 53%
    • Insoluble fibre
      -1.4no signal · 32%
    • Simple carbohydrates
      +0.8no signal · 15%
    • Alcohol
      -0.3no signal · 15%
    • Dietary fat load
      +0.1no signal · 15%

    DeepGene damage signature

    The metagenomic + host-DNA read-out that initializes this patient's biology and, on retest, measures whether the steering worked.

    Damage score · retest day 90
    37/100
    vs baseline (day 0)
    -4
    5 improved · 1 worsened
    synthetic signature · consistent with this patient's biology
    • 2 opportunists above range: Escherichia coli, Clostridioides difficile
    • 2 keystone species absent
    • 4 resistance genes
    • Tissue recycling index 36
    Pathogens / opportunists2/5
    Keystone species2/8
    from 3
    Diversity0/2
    from 1
    Metabolic modules0/4
    Vitamin synthesis2/7
    Oral translocation1/1
    Host DNA0/1
    Tissue recycling1/1
    from 0
    Central mechanisms0/2
    Virulence factors2/2
    from 3
    Antibiotic resistance genes4/4
    from 6
    Genetic predisposition2/2
    Opportunists above range
    Escherichia coli 11.584% AR
    Clostridioides difficile 1.158% AR
    Keystone species absent
    Akkermansia muciniphila, Bifidobacterium longum
    Capacity
    Shannon 3.17 · butyrate 739 CPM · SCFA 1178
    2 vitamins below
    Host & mechanisms
    tissue recycling 36/100
    oral translocation 2.66% AR
    4 resistance genes · 2 virulence factors

    Biological layers

    Which pathways look influenced, and by which layer of this person's biology.

    Pathways under pressure
    • Butyrate / short-chain fatty acid production 25
      • MicrobiomeF. prausnitzii depleted
    DNA
    Fictional pharmacogenomic panel
    • CYP2D6 Normal metabolizer
      Expected exposure
    • GLP1R rs6923761 A
      Altered receptor sensitivity
    Microbiome
    Shannon diversity 4.6 · butyrate capacity 53/100
    • Akkermansia muciniphilaNormal
    • Faecalibacterium prausnitziiLow
    • Bacteroides fragilisNormal
    • Bifidobacterium longumLow
    • EnterobacteriaceaeNormal
    Wearable, last 14 days
    daily evolution fed into the runtime
    HRV
    39 ms
    Sleep
    6.8 h
    Steps
    7,144
    Resting HR
    59 bpm
    Daily log: GI score 13, nutritional resilience 66, adherence 88.

    What this patient sees in NostraAI

    The content that steers the trajectory: what to eat, what to do, what to take.

    Open companion preview
    What to eat
    • Keep meals regular; three to four moderate portions spaced through the day
    • Include a cooked vegetable portion with each main meal
    • Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
    • Eat slowly and stop at comfortable fullness — smaller volume, more often
    What to do
    • Log the daily check-in; one line is enough
    • Keep the current walking rhythm
    • Keep the sleep window steady
    • Keep hydration steady: small amounts through the day rather than large volumes at once
    What to take
    • Take the dose at the same time relative to your evening meal
    • No additional supplements this week
    • Fictional demo item: continue vitamin D as before

    284 biologically similar trajectories

    Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

    PatientSimilarityBaselineInterventionOutcomeResponse today
    P-0217952%S03100
    P-0217651%S0697
    P-0225450%S1190
    P-0200649%S0291
    P-0269949%S0890
    P-0263148%S1696
    P-0234547%S0489
    P-0268647%S0587
    P-0207446%S1792
    P-0219946%S1888
    P-0224646%S0286
    P-0253146%S1788